Shandong Boan Biotech Co Ltd

Shandong Boan Biotechnology Co., Ltd. is a biopharmaceutical company that develops, manufactures, and markets biologics in Mainland China. Its products include Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for various cancers; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody targeting RANK ligand for osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody for bone metastases and giant cell tumor of bone. The company is also developing several drug candidates, including BA5101 for type 2 diabetes, BA9101 for ophthalmic use, and others in clinical trials. Founded in 2013 and headquartered in Yantai, China, it is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd.